Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
341-360 of 1,307 trials

Dapagliflozin for Patients Undergoing Heart Bypass Surgery

We are studying whether dapagliflozin can help prevent new heart rhythm problems and kidney issues in patients awaiting coronary artery bypass surgery. This research aims to improve recovery and overall outcomes after surgery.

Atrial Fibrillation and Acute Kidney Injury after CABG3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyInternal MedicineNephrology

DLBCL Treatment: Dexrazoxane for Heart Protection

We are studying whether dexrazoxane can help prevent heart problems in patients with diffuse large B-cell lymphoma receiving chemotherapy. This trial will also compare treatment responses and monitor any side effects.

Diffuse Large B-Cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyOncology

Multiple Sclerosis: Annual vs. Semi-Annual Ocrelizumab Infusions

We are comparing the effects of annual and semi-annual infusions of ocrelizumab in patients with active multiple sclerosis. The goal is to see which schedule better prevents disease activity over two years.

Multiple Sclerosis1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurology

Stomach Cancer: MK-2870 Treatment Study

We are comparing a new treatment called MK-2870 to standard care for people with advanced stomach cancer. The goal is to see if MK-2870 can improve survival and manage symptoms better.

Adenocarcinoma of the Gastroesophageal Junction>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Memory Disorders: Evaluating Tau PET Imaging

We are studying whether tau PET can improve diagnosis for patients with memory problems. This trial compares its effectiveness to more common and affordable diagnostic tools.

Mild Cognitive Impairment and Dementia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurology

Follicular Lymphoma: Mosunetuzumab and Lenalidomide Study

We are evaluating a new combination treatment for people with untreated follicular lymphoma to see if it works better than standard chemotherapy. This study aims to improve patient outcomes and quality of life.

Follicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Heart Attack Prevention: Selatogrel Study

We are studying whether self-administering selatogrel can help prevent further heart attacks in individuals with a recent heart attack history. The trial also looks at the safety of this self-administration.

Heart Attack>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Erosive Esophagitis: NEXIUM for Kids

We are studying whether NEXIUM can help maintain healing in children aged 1 to 11 with erosive esophagitis. This trial also looks at how well the medication works and any symptoms during treatment.

Erosive Esophagitis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Primary Aldosteronism: [68Ga]Ga-PentixaFor PET Imaging Study

We are evaluating a new imaging method to help identify how adrenal glands secrete aldosterone in patients with primary aldosteronism. This may improve diagnosis and treatment options for those affected.

Primary Hyperaldosteronism>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

Acyclovir for ICU Patients with Herpes Simplex Virus Reactivation

We are studying whether acyclovir can help reduce mortality and improve recovery in intubated patients with Herpes simplex virus reactivation. This trial compares acyclovir to a placebo to see which treatment is more effective.

Herpes Simplex Reactivation>2 yearsConfirmation phase (III)Standard MedicinesInfectious DiseasesInternal Medicine

Acute Myeloid Leukemia: Comparing Conditioning Regimens in Children

We are studying two different treatment plans for children with Acute Myeloid Leukemia undergoing stem cell transplants. Our goal is to find out which plan leads to better survival and fewer side effects.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Giant Cell Arteritis: Stopping Tocilizumab

We are comparing immediate versus gradual stopping of tocilizumab in patients with giant cell arteritis. The goal is to see which method helps prevent relapses and improves quality of life.

Giant Cell Arteritis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesRheumatology

Pulmonary Arterial Hypertension: Treprostinil Palmitil Inhalation Powder

We are studying the long-term safety and effects of an inhalation powder for people with pulmonary arterial hypertension. This research aims to see if it improves exercise capacity and overall health.

Pulmonary Arterial Hypertension1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Immune Thrombocytopenia: Avatrombopag vs. Rituximab

We are comparing the effectiveness of Avatrombopag and Rituximab in adults with ITP who did not respond to corticosteroids. The study aims to see which treatment better improves health-related quality of life and reduces fatigue.

Immune Thrombocytopenia1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInternal Medicine

Carcinoma of Unknown Primary: [18F]F-FAPI PET-CT Study

We are investigating whether [18F]F-FAPI PET-CT can help identify the primary tumor in patients with carcinoma of unknown primary. This study aims to improve diagnosis and treatment options for these patients.

Carcinoma of Unknown Primary>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Migraine in Adolescents: Rimegepant Study

We are investigating whether rimegepant can help prevent migraines in adolescents aged 12 to under 18 with chronic migraine. The study will also assess its safety and how it affects the use of other migraine treatments.

Chronic Migraine1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Head and Neck Cancer: Ficlatuzumab and Cetuximab Study

We are investigating whether the combination of ficlatuzumab and cetuximab improves survival in adults with recurrent or metastatic HPV-negative head and neck cancer. This study compares the effects of this combination to a placebo treatment.

Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

Lupus Treatment: BIIB059 Study

We are testing a new medication, BIIB059, for people with active subacute or chronic cutaneous lupus who haven't responded to standard treatments. The study aims to see if it can reduce skin disease activity and improve overall safety.

Skin Lupus1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Atypical Hemolytic Uremic Syndrome: Crovalimab for Kids

We are studying the safety and effectiveness of crovalimab in children with atypical hemolytic uremic syndrome. This trial includes both new patients and those switching from other treatments.

Atypical Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyNephrology

Cholangiocarcinoma: Tinengotinib Study

We are studying the safety and effectiveness of a new oral medication, tinengotinib, for patients with FGFR-altered cholangiocarcinoma that hasn't responded to other treatments. This trial compares tinengotinib to the physician's choice of treatment.

Cholangiocarcinoma6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology